PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Microbes Infect. Author manuscript; available in PMC Jul 1, 2009.
Published in final edited form as:
PMCID: PMC2586805
NIHMSID: NIHMS78141
HISTOPLASMA CAPSULATUM AT THE HOST-PATHOGEN INTERFACE
Joshua D. Nosanchuk1* and Attila Gacser2
1Departments of Medicine (Infectious Diseases) and Microbiology/Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
2Department of Microbiology, University of Szeged, Szeged, Közép fasor 52, H-6726, Hungary
* Address correspondence to: J.D. Nosanchuk, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461. Phone: 718-430-3766. Fax: 718-430-8701. nosanchu/at/aecom.yu.edu
Abstract
Histoplasma capsulatum is the most common cause of invasive fungal pulmonary disease worldwide. The interaction of H. capsulatum with a host is a complex, dynamic process. Severe disease most commonly occurs in individuals with compromised immunity, and the increasing utilization of immunomodulators in medicine has revealed significant risks for reactivation disease in patients with latent histoplasmosis. Fortunately, there are well developed molecular tools and excellent animal models for studying H. capsulatum virulence and numerous recent advances have been made regarding the pathogenesis of this fungus that will improve our capacity to combat disease.
Keywords: Histoplasma capsulatum, pathogenesis, genetics, vaccine, antibody
Fungal pathogens continue to gain clinical importance largely due to the increasing number of immunocompromised individuals worldwide. The dimorphic fungus Histoplasma capsulatum var. capsulatum is a model pathogen for the study of invasive mycotic disease. H. capsulatum is primarily acquired via aerosol exposure with the inhalation of microconidia or hyphal fragments. It has been estimated that H. capasulatum is responsible for ~500,000 infections in the USA each year, making it the most prevalent pulmonary fungal pathogen [1]. H. capsulatum produces a broad spectrum of disease ranging from a mild influenza-like illness to a disseminated form that may involve virtually any tissue. The fungus is endemic worldwide, but there are regions with notably high incidences of infection [2], such as areas along the Ohio and Mississippi River Valleys in the USA and in Rio de Janeiro State in Southeastern Brazil.
Although the majority of symptomatic infections follow primary exposures to H. capsulatum, reactivation of latent infection can result in significant disease, particularly in the setting of immunosuppression such as with individuals chronically receiving steroids or patients on chemotherapy [3]. Individuals with advanced HIV disease are also at significant risk for severe infection due to reactivation of latent lesions or primary disease, and disseminated disease occurs in 95% of individuals with AIDS [4]. Also, initiation of HAART in patients with prior infection with H. capsulatum can result in an immune reconstitution inflammatory syndrome [5]. Furthermore, reactivation disease can develop in liver transplant recipients with disease originating from latent infections in the transplanted organs [6]. Additionally, reactivation histoplasmosis has increasingly occurred in patients receiving anti-cytokine therapies, especially inhibitors of TNF- α [reviewed in [7]]. Hence, disease severity and the manifestations of histoplasmosis are significantly impacted by the competence of the host immune response.
The outcome of infection with H. capsulatum is dependent on dynamic interactions between innate immunity, adaptive immunity and fungal virulence factors [8]. Control of H. capsulatum infection is largely based on activation of cellular immunity in concert with innate responses, as progressive disease with dissemination predominantly occurs in the absence of intact cellular immunity [9]. Interestingly, there is recent experimental evidence demonstrating that susceptibility to H. capsulatum strongly depends on genetic predisposition [10].
T cells and phagocytes are essential to host resistance against H. capsulatum [9, 11]. Protective immunity is characterized by the induction of cytokine production by T cells, particularly IFN-γ and TNF-α, which subsequently activate phagocytic cells. The primary effector cells in host resistance to H. capsulatum are macrophages. However, the role of macrophages in histoplasmosis is complex, since these cells also provide a protective environment for H. capsulatum as the fungus survives and replicates in the phagolysosomes of macrophages. In contrast, dendritic cells can kill ingested H. capsulatum yeast cells [12] and dendritic cells presenting H. capsulatum antigens can stimulate specific CD8+ T cells to effectively control fungal infection [13].
TNF-α production is induced rapidly after primary infection and neutralization of TNF-α increases the fungal burden and mortality of mice infected with H. capsulatum [14, 15]. Inhibition of TNF-α results in the generation of antigen specific CD4+CD25+ T cells that interfere with effective immunity in mice [16]. The experimental findings correlate with the clinical findings that inhibitors of TNF-α greatly increase the risk for reactivation of latent histoplasmosis resulting in severe diseases [7].
Mice deficient in IFN-γ have accelerated mortality [17]. Similarly, patients with defects in IFN-γ signaling are at risk for severe histoplasmosis [18]. Adjuvant therapy with IFN-γ can improve the outcome of murine histoplasmosis [19] and has been used successfully in a child with a defect in his IFN-γ receptor [18].
H. capsulatum induces the production of antibodies, which historically has provided a means for non-culture based methods of diagnosis [20]. Notably, antibody has been shown to affect H. capsulatum pathogenesis in an animal model [21]. Supporting a role of antibody in histoplasmosis, mice lacking B cells have accelerated mortality after experimental reactivation histoplasmosis [22].
H. capsulatum is mycelial in the environment, whereas the organism exists as a yeast-like, unicellular fungus that reproduces by budding at human physiological temperatures. The mechanisms controlling the switch from the mycelial to the yeast form of H. capsulatum are complex, but are largely dependent on the shift in temperature and availability of nutrients [reviewed in [23]]. The fungus is a prototypical intracellular pathogen that survives within phagolysomes by regulating the intracellular milieu of macrophages [reviewed in [24]].
In addition to dimorphism, several virulence determinants of H. capsulatum have been characterized. Perhaps the best studied is the heat shock protein 60 that serves as the ligand for H. capsulatum binding to CR3 on macrophage, which initiates the fungus’ intracellular parasitism of these cells [25]. H. capsulatum heat shock proteins are upregulated during the mycelia-yeast transition and are broadly involved in chaperoning of proteins. The M and H antigens of H. capsulatum have long been utilized as serological markers of histoplasmosis [20]. The M antigen, also known as Catalase B, is a constitutively expressed protein posited to play a role in counteracting the oxidative defense reaction mechanism of host phagocytic cells [26]. The H antigen is a secreted beta-glucosidases purportedly involved in remodeling of the cell wall and nutrient acquisition [27]. Initially identified in a differential hybridization screen, yeast phase specific protein 3 (YPS3) is a cell surface and secreted protein of uncertain function that has been associated with virulence since silencing of the YPS3 gene significantly attenuates virulence in vitro and during murine infection [28]. H. capsulatum secretes a calcium binding protein (CBP) during yeast-phase growth that is essential for growth in calcium limiting conditions, such as encountered in vivo, and required for virulence during murine infection [29]. Although certain strains of H. capsulatum have lost alpha-(1,3)- glucans from their cell surface during microevolution events and have maintained virulence, strains that display alpha-(1,3)-glucans on their cell surface are severely attenuated if the production of this glucan is disrupted. Also, deletion or silencing of alpha-(1,3)-glucan synthase [30] or alpha-(1,4)-amylase [31] interferes with alpha-(1,3)-glucans and the resulting mutants have significantly reduced virulence. Interestingly, alpha-(1,3)-glucans inhibit the recognition of H. capsulatum from host effector cells by blocking the beta-glucan receptor dectin-1 [32]. H. capsulatum produces melanin in its cell wall [33] that protects the fungus from antifungal drugs [34] and the pigment is also thought to inhibit damage from host defenses, including host derived free radicals and microbicidal peptides [35].
Several studies have described genetic and/or genomic heterogeneity among H. capsulatum isolates based on restriction fragment length polymorphisms (RFLP), arbitrary-primer PCR analysis, ribosomal DNA sequencing and other gene sequencing comparisons (reviewed in [36]). Molecular characterization studies have identified seven genetically distinguishable phylogenetic species that diverged as much as 13 million years ago. For example, there are two discrete genetic lineages in North America, Histoplasma class I (NAm I) and Histoplasma class II (NAm II) that also differ significantly in virulence [37]. Currently, the sequencing of the genome of H. capsulatum is underway at Washington University for NAm II (http://genome.wustl.edu/genome.cgi?GENOME=Histoplasma%20capsulatum) and at the Broad Institute for NAm I (http://www.broad.mit.edu/annotation/genome/histoplasma_capsulatum/Home.html). The sequence data may clarify the genomic basis for the difference in virulence and interactions with the host immune system, and serves as a rich resource for molecular work on this pathogen.
The development of molecular genetic tools in H. capsulatum is essential for elucidating important questions, such as the mechanisms for mycelia to yeast phase transition, survival in macrophages, and regulation of virulence associated factors. Although, H. capsulatum is a perfect fungus with a characterized sexual cycle, laboratory strains cultured in vitro rapidly lose the ability to mate [38], significantly complicating the application of classic recombination studies. Also, the sexual mould form requires BSLIII conditions. The first H. capsulatum mutants were URA5 auxotrophs created using UV radiation [39]. Subsequent transformation experiments for genetic complementation showed that the bacterial plasmid constructs containing the Podospora anserina URA5 gene usually integrated randomly, and often tandem amplifications or rearrangements were present. Analysis of introduced foreign DNA revealed that H. capsulatum actively modifies transforming plasmids, adding guanosine rich hexanucleotide repeats to the ends of the linear DNA fragments [40]. Subsequent developments exploited the autonomous replication potential of the presented foreign DNA and telomeric shuttle vectors were constructed for genetic complementation in uracil auxotrophs [41]. The first gene targeting experiment deleted the URA5 gene in H. capsulatum [42]. The bacterial hygromycin resistance gene (hph) was used to delete the target gene, allowing positive selection. However, the transformation experiments showed a very low (1.4 × 10-3) homologous recombination frequency. To prevent the high frequency of illegitimate integration, a two-step gene knock-out strategy has been develop using telomeric linear plasmids that enable the creation of homologous recombinant mutants [29]. More recently, double stranded RNA induced RNA interference has been successfully used for target gene expression silencing in numerous eukaryotes [30]. In addition to introducing foreign DNA by electroporation and biolistic procedures, an Agrobacterium tumefaciens mediated transfection method has proven to be the most efficient method for DNA transformation in H. capsulatum [43]. In particular, the A. tumefaciens T-DNA technique readily allows for forward genetic screens and can be a powerful approach to identify virulence associated genes.
There is a general consensus among medical mycologist that there is sufficient disease due to H. capsulatum to merit the development of a vaccine. The knowledge that immunization of mice with sublethal inocula of H. capsulatum induces protective immunity to subsequent lethal challenge suggests that an effective human vaccine can be achieved. Since the 1970’s we have known that immunization with H. capsulatum ribosomes confers protective responses [44, 45]. However, major advances in vaccinology for histoplasmosis came with the finding that recombinant heat shock protein 60 from H. capsulatum induces vigorous protective immune responses that primarily depend on Vβ 8.1/8.2+ CD4+ T cells [46, 47]. Interestingly, immunization with a second heat shock protein of 70 kDa does not result protective cellular responses [48]. More recently, it has been shown that CD8+ T cells can confer protection following immunization with heat shock protein 60 in the absence of CD4+ cells, and that CD8+ T cells can be efficiently stimulated by dendritic cells [13]. The findings are significant since they indicate that it may be possible to induce protective responses in individuals with altered immunity, including individuals with advanced HIV infection.
Although heat shock protein 60 has been the major focus of vaccine development for H. capsulatum, additional targets have been identified. For example, protection from pulmonary infection can also be achieved in mice with immunization with recombinant H antigen [49]. Immunization with purified cell free antigen mixtures from H. capsulatum can protect mice from systemic infection [50]. Protective immunity is also achievable with recombinant H. capsulatum Sec31 [51]. Futhermore, efforts are underway to define pan-fungal vaccine targets. A hybrid histidine kinase that is a global regulator of mycelia-yeast morphogenesis has been identified in the major dimorphic fungi, including H. capsulatum, and gene deleted strains may be used for vaccines [52]. A second potential method for a universal fungal vaccine is the utilization of beta-glucans [53]. Hence, there are several exciting avenues for the pursuit of a safe and effective vaccine for histoplasmosis.
We have shown that antibody can modify the pathogenesis of experimental histoplasmosis [21]. Although the protective effects of IgM isotype monoclonal antibodies (mAbs) that target histone 2B on the fungal cell wall were modest, survival significantly improved when antibody was used concomitantly with amphotericin B. We have more recently identified protective mAbs to the M antigen and heat shock protein 60 and the IgG isotype mAbs that target these proteins appear to be more effective therapeutics for histoplasmosis [54].
Recently, we found that negative costimulation pathways play a critical role in H. capsulatum pathogenesis [55]. The PD-1/PD-L interaction inhibits T cell activation and it has been exploited by a variety of viruses, parasites, and bacteria to attenuate antimicrobial immunity and enhance survival in the host [56]. Using our experimental murine infection model with H. capsulatum, we determined that PD-L1 is upregulated on alveolar and peritoneal macrophages as well as on all mononuclear cells in the lungs and splenocytes. The absence of negative co-stimulation significantly alters the fate of mice challenged with H. capsulatum, where all mice deficient in PD-1 and 70% of mice receiving antibody to block PD-1 survived an otherwise lethal infection [55].
6. Summary
H. capsulatum is a fungus with a worldwide distribution that is one of the most common systemic mycoses of humans. Despite the availability of broad spectrum antifungal agents and intensive care units, the mortality rate from this fungus continues to be unacceptably high. Recent developments including the availability of genomic information, methods for generating gene deficient strains, and increased understanding of host responses to infection and vaccination are providing important insights that will lead to improved care of patients with histoplasmosis.
TABLE 1
TABLE 1
MOLECULAR TOOL BOX BY DATE DEVELOPED FOR USE IN H. CAPSULATUM
Acknowledgments
JDN is supported in part by NIH AI056070-01A2. Because of space restrictions, we were able to cite only a fraction of the relevant literature and apologize to colleagues whose contributions may not be appropriately acknowledged in this paper.
Footnotes
Conflict of Interests The authors have no conflicts.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1. Cano MV, Hajjeh RA. The epidemiology of histoplasmosis: a review. Semin Respir Infect. 2001;16:109–118. [PubMed]
2. Kwon-Chung KJ, Bennett JE. Histoplasmosis. In: Kwon-Chung KJ, Bennett JE, editors. Medical Mycology. Lea and Febiger; Philadelphia: 1992. pp. 464–513.
3. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20:115–132. [PMC free article] [PubMed]
4. Wheat J. Histoplasmosis in the acquired immunodeficiency syndrome. Curr Top Med Mycol. 1996;7:7–18. [PubMed]
5. Breton G, Adle-Biassette H, Therby A, Ramanoelina J, Choudat L, Bissuel F, Huerre M, Dromer F, Dupont B, Lortholary O. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. Aids. 2006;20:119–121. [PubMed]
6. Limaye AP, Connolly PA, Sagar M, Fritsche TR, Cookson BT, Wheat LJ, Stamm WE. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med. 2000;343:1163–1166. [PubMed]
7. Deepe GS., Jr Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis. 2005;41:S204–207. [PubMed]
8. Casadevall A, Pirofski L. Host-pathogen interactions: the attributes of virulence. J Infect Dis. 2001;184:337–344. [PubMed]
9. Allendorfer R, Brunner GD, Deepe GS., Jr Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. J Immunol. 1999;162:7389–7396. [PubMed]
10. Mayfield JA, Rine J. The genetic basis of variation in susceptibility to infection with Histoplasma capsulatum in the mouse. Genes Immun. 2007;8:468–474. [PubMed]
11. Gomez FJ, Cain JA, Gibbons R, Allendoerfer R, Deepe GS., Jr Vbeta4(+) T cells promote clearance of infection in murine pulmonary histoplasmosis. J Clin Invest. 1998;102:984–995. [PMC free article] [PubMed]
12. Gildea LA, Morris RE, Newman SL. Histoplasma capsulatum yeasts are phagocytosed via very late antigen-5, killed, and processed for antigen presentation by human dendritic cells. J Immunol. 2001;166:1049–1056. [PubMed]
13. Lin JS, Yang CW, Wang DW, Wu-Hsieh BA. Dendritic cells cross-present exogenous fungal antigens to stimulate a protective CD8 T cell response in infection by Histoplasma capsulatum. J Immunol. 2005;174:6282–6291. [PubMed]
14. Zhou P, Miller G, Seder RA. Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma. J Immunol. 1998;160:1359–1368. [PubMed]
15. Allendoerfer R, Deepe GS., Jr Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol. 1998;160:6072–6082. [PubMed]
16. Deepe GS, Jr, Gibbons RS. TNF-{alpha} antagonism generates a population of antigen-specific CD4+CD25+ T Cells that inhibit protective immunity in murine histoplasmosis. J Immunol. 2008;180:1088–1097. [PMC free article] [PubMed]
17. Clemons KV, Darbonne WC, Curnutte JT, Sobel RA, Stevens DA. Experimental histoplasmosis in mice treated with anti-murine interferon-gamma antibody and in interferon-gamma gene knockout mice. Microbes Infect. 2000;2:997–1001. [PubMed]
18. Zerbe CS, Holland SM. Disseminated histoplasmosis in persons with interferon-gamma receptor 1 deficiency. Clin Infect Dis. 2005;41:e38–41. [PubMed]
19. Clemons KV, Lutz JE, Stevens DA. Efficacy of interferon-gamma and amphotericin B for the treatment of systemic murine histoplasmosis. Microbes Infect. 2001;3:3–10. [PubMed]
20. Guimarães A, Nosanchuk JD, Zancope-Oliveira RM. Diagnosis of histoplasmosis. Brazilian Journal of Microbiology. 2006;37:1–13. [PMC free article] [PubMed]
21. Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS, Jr, Casadevall A. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest. 2003;112:1164–1175. [PMC free article] [PubMed]
22. Allen HL, Deepe GS., Jr B cells and CD4-CD8- T cells are key regulators of the severity of reactivation histoplasmosis. J Immunol. 2006;177:1763–1771. [PubMed]
23. Woods JP. Histoplasma capsulatum molecular genetics, pathogenesis, and responsiveness to its environment. Fungal Genet Biol. 2002;35:81–97. [PubMed]
24. Newman SL. Macrophages in host defense against Histoplasma capsulatum. Trends Microbiol. 1999;7:67–71. [PubMed]
25. Long KH, Gomez FJ, Morris RE, Newman SL. Identification of heat shock protein 60 as the ligand on Histoplasma capsulatum that mediates binding to CD18 receptors on human macrophages. J Immunol. 2003;170:487–494. [PubMed]
26. Zancope-Oliveira RM, Reiss E, Lott TJ, Mayer LW, Deepe GS., Jr Molecular cloning, characterization, and expression of the M antigen of Histoplasma capsulatum. Infect Immun. 1999;67:1947–1953. [PMC free article] [PubMed]
27. Fisher KL, Woods JP. Determination of beta-glucosidase enzymatic function of the Histoplasma capsulatum H antigen using a native expression system. Gene. 2000;247:191–197. [PubMed]
28. Bohse ML, Woods JP. RNA interference-mediated silencing of the YPS3 gene of Histoplasma capsulatum reveals virulence defects. Infect Immun. 2007;75:2811–2817. [PMC free article] [PubMed]
29. Sebghati TS, Engle JT, Goldman WE. Intracellular parasitism by Histoplasma capsulatum: fungal virulence and calcium dependence. Science. 2000;290:1368–1372. [PubMed]
30. Rappleye CA, Engle JT, Goldman WE. RNA interference in Histoplasma capsulatum demonstrates a role for alpha-(1,3)-glucan in virulence. Mol Microbiol. 2004;53:153–165. [PubMed]
31. Marion CL, Rappleye CA, Engle JT, Goldman WE. An alpha-(1,4)-amylase is essential for alpha-(1,3)-glucan production and virulence in Histoplasma capsulatum. Mol Microbiol. 2006;62:970–983. [PubMed]
32. Rappleye CA, Eissenberg LG, Goldman WE. Histoplasma capsulatum alpha-(1,3)-glucan blocks innate immune recognition by the beta-glucan receptor. Proc Natl Acad Sci U S A. 2007;104:1366–1370. [PubMed]
33. Nosanchuk JD, Gomez BL, Youngchim S, Diez S, Aisen P, Zancope-Oliveira RM, Restrepo A, Casadevall A, Hamilton AJ. Histoplasma capsulatum synthesizes melanin-like pigments in vitro and during mammalian infection. Infect Immun. 2002;70:5124–5131. [PMC free article] [PubMed]
34. Van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibility to amphotericin B and caspofungin. Antimicrob Agents Chemother. 2002;46:3394–3400. [PMC free article] [PubMed]
35. Nosanchuk JD, Casadevall A. Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother. 2006;50:3519–3528. [PMC free article] [PubMed]
36. Magrini V, Goldman WE. Molecular mycology: a genetic toolbox for Histoplasma capsulatum. Trends Microbiol. 2001;9:541–546. [PubMed]
37. Kasuga T, White TJ, Koenig G, McEwen J, Restrepo A, Castaneda E, Da Silva Lacaz C, Heins-Vaccari EM, De Freitas RS, Zancope-Oliveira RM, Qin Z, Negroni R, Carter DA, Mikami Y, Tamura M, Taylor ML, Miller GF, Poonwan N, Taylor JW. Phylogeography of the fungal pathogen Histoplasma capsulatum. Mol Ecol. 2003;12:3383–3401. [PubMed]
38. Kwon-Chung KJ, Weeks RJ, Larsh HW. Studies on Emmonsiella capsulata (Histoplasma capsulatum). II. Distribution of the two mating types in 13 endemic states of the United States. Am J Epidemiol. 1974;99:44–49. [PubMed]
39. Worsham PL, Goldman WE. Selection and characterization of ura5 mutants of Histoplasma capsulatum. Mol Gen Genet. 1988;214:348–352. [PubMed]
40. Woods JP, Goldman WE. Autonomous replication of foreign DNA in Histoplasma capsulatum: role of native telomeric sequences. J Bacteriol. 1993;175:636–641. [PMC free article] [PubMed]
41. Woods JP, Goldman WE. In vivo generation of linear plasmids with addition of telomeric sequences by Histoplasma capsulatum. Mol Microbiol. 1992;6:3603–3610. [PubMed]
42. Woods JP, Heinecke EL, Goldman WE. Electrotransformation and expression of bacterial genes encoding hygromycin phosphotransferase and beta-galactosidase in the pathogenic fungus Histoplasma capsulatum. Infect Immun. 1998;66:1697–1707. [PMC free article] [PubMed]
43. Sullivan TD, Rooney PJ, Klein BS. Agrobacterium tumefaciens integrates transfer DNA into single chromosomal sites of dimorphic fungi and yields homokaryotic progeny from multinucleate yeast. Eukaryot Cell. 2002;1:895–905. [PMC free article] [PubMed]
44. Feit C, Tewari RP. Immunogenicity of ribosomal preparations from yeast cells of Histoplasma capsulatum. Infect Immun. 1974;10:1091–1097. [PMC free article] [PubMed]
45. Garcia JP, Howard DH. Characterization of antigens from the yeast phase of Histoplasma capsulatum. Infect Immun. 1971;4:116–125. [PMC free article] [PubMed]
46. Deepe GS, Jr, Gibbons RS. Cellular and molecular regulation of vaccination with heat shock protein 60 from Histoplasma capsulatum. Infect Immun. 2002;70:3759–3767. [PMC free article] [PubMed]
47. Gomez FJ, Allendoerfer R, Deepe GS., Jr Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis. Infect Immun. 1995;63:2587–2595. [PMC free article] [PubMed]
48. Allendoerfer R, Maresca B, Deepe GS., Jr Cellular immune responses to recombinant heat shock protein 70 from Histoplasma capsulatum. Infect Immun. 1996;64:4123–4128. [PMC free article] [PubMed]
49. Deepe GS, Jr, Gibbons R. Protective efficacy of H antigen from Histoplasma capsulatum in a murine model of pulmonary histoplasmosis. Infect Immun. 2001;69:3128–3134. [PMC free article] [PubMed]
50. Sa-Nunes A, Medeiros AI, Nicolete R, Frantz FG, Panunto-Castelo A, Silva CL, Faccioli LH. Efficacy of cell-free antigens in evaluating cell immunity and inducing protection in a murine model of histoplasmosis. Microbes Infect. 2005;7:584–592. [PubMed]
51. Scheckelhoff MR, Deepe GS., Jr Pulmonary V beta 4+ T cells from Histoplasma capsulatum-infected mice respond to a homologue of Sec31 that confers a protective response. J Infect Dis. 2006;193:888–897. [PMC free article] [PubMed]
52. Nemecek JC, Wuthrich M, Klein BS. Global control of dimorphism and virulence in fungi. Science. 2006;312:583–588. [PubMed]
53. Cutler JE, Deepe GS, Jr, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol. 2007;5:13–28. [PMC free article] [PubMed]
54. Guimarães AJ, Williams DA, Zancope-Oliveira RM, Nosanchuk JD. ASM Conference on Dimorphic Fungal Pathogens. ASM; Denver, CO: 2006. Protective antibodies to Histoplasma capsulatum cell surface antigens: heat shock protein 60 and M antigen (Abstract B35) p. 42.
55. Lazar-Molnar E, Gacser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk JD. The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proc Natl Acad Sci U S A. 2008;105:2658–2663. [PubMed]
56. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239–245. [PubMed]
57. Worsham PL, Goldman WE. Development of a genetic transformation system for Histoplasma capsulatum: complementation of uracil auxotrophy. Mol Gen Genet. 1990;221:358–362. [PubMed]
58. Kugler S, Young B, Miller VL, Goldman WE. Monitoring phase-specific gene expression in Histoplasma capsulatum with telomeric GFP fusion plasmids. Cell Microbiol. 2000;2:537–547. [PubMed]
59. Gebhart D, Bahrami AK, Sil A. Identification of a copper-inducible promoter for use in ectopic expression in the fungal pathogen Histoplasma capsulatum. Eukaryot Cell. 2006;5:935–944. [PMC free article] [PubMed]
60. Hwang L, Hocking-Murray D, Bahrami AK, Andersson M, Rine J, Sil A. Identifying phase-specific genes in the fungal pathogen Histoplasma capsulatum using a genomic shotgun microarray. Mol Biol Cell. 2003;14:2314–2326. [PMC free article] [PubMed]
61. Romero-Martinez R, Curiel-Quesada E, Becerril-Lujan B, Flores-Carreon A, Perez-Torres A, Taylor ML. Detection of constitutive molecules on Histoplasma capsulatum yeasts through single chain variable antibody fragments displayed in M13 phages. FEMS Immunol Med Microbiol. 2007;50:77–85. [PubMed]